Vitronectin's basic domain is a syndecan ligand which functions in trans to regulate vitronectin turnover

Cell Communication and Adhesion

Volumn 10, Issue 2, 2003, Pages 85-103

  Wilkins Port, Cynthia E ^a   Sanderson, Ralph D ^b   Tominna Sebald, Eiman ^a   McKeown Longo, Paula J ^a  

^a ALBANY MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Heparin binding domain; Syndecan; Vitronectin

Indexed keywords

GLUTATHIONE TRANSFERASE; GLYPICAN; HEPARIN BINDING PROTEIN; HYBRID PROTEIN; RECOMBINANT PROTEIN; SYNDECAN; SYNDECAN 1; SYNDECAN 2; SYNDECAN 4; VIRUS VECTOR; VITRONECTIN;

AMINO ACID SEQUENCE; BACULOVIRUS; BINDING SITE; CELL ADHESION; CELL LINE; CELL SURFACE; CONTROLLED STUDY; EXTRACELLULAR MATRIX; FIBROBLAST; GENE DELETION; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN METABOLISM; REGULATORY MECHANISM; REVIEW; SEQUENCE ANALYSIS; SKIN CELL; WILD TYPE;

UNIDENTIFIED BACULOVIRUS;

EID: 0346398517     PISSN: 15419061     EISSN: None     Source Type: Journal    
DOI: 10.1080/cac.10.2.85.103     Document Type: Review

References (97)

1. Aaboe M, Offersen BV, Christensen A, Andreasen PA (2003). Vitronectin in human breast carcinomas. Biochim Biophys Acta 1638: 72-82.
2. Adams JC, Kureishy N, Taylor AL (2001). A role for Syndecan-1 in coupling fascin spike formation by thrombospondin-1. J Cell Biol 152: 1169-1182.
3. Baeuerle PA, Huttner WB (1986). Chlorate - A potent inhibitor of protein sulfation in intact cells. Biochem Biophys Res Comm 141: 870-877.
4. Bernfield M, Gotte M, Park P, Reizes O, Fitzgerald M (1999). Functions of cell surface heparan sulfate proteoglycans. Ann Rev Biochem 68: 729-778.
5. Cardin AD, Weintraub HJR (1989). Molecular modeling of protein-glycosaminoglycan interactions. Atherosclerosis 9: 21-31.
6. Carreiras F, Cruet S, Staedel C, Sichel F, Gauduchon P (1999). Human ovarian adenocarcinoma cells synthesize vitronectin and use it to organize their adhesion. Gynecol Oncol 72: 312-322.
7. v integrins and their ligand vitronectin in normal ovarian epithelium and in ovarian carcinoma. Gynecol Oncol 62: 260-267.
8. Chain D, Korc-Grodzicki B, Kreizman T, Shaltiel S (1991). Endogenous cleavage of the Arg-379-Ala-380 bond in vitronectin results in a distinct conformational change which 'buries' Ser-378, its site of phosphorylation by protein kinase A. Biochem J 274: 387-394.
9. Cherny RC, Honan MA, Thiagarajan P (1993). Site-directed mutagenesis of the arginine-glycine-aspartic acid in vitronectin abolishes cell adhesion. J Biol Chem 268: 9725-9729.
10. Couchman JR, Chen L, Woods A (2001). Syndecans and cell adhesion. Int Rev Cytol 207: 113-150.
11. Crossen R, Gruenwald S (1997). Baculovirus Expression Vector System Manual, 4th ed., PharMingen, San Diego, CA, pp. 22-35.
12. Czekay R-P, Aertgeerts K, Curriden SA, Loskutoff D (2003). Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins. J Cell Biol 160: 781-791.
13. Dalton A, McFarland CD, Underwood PA, Steele JG (1995). Role of the heparin binding domain of fibronectin in attachment and spreading of human bone derived cells. J Cell Sci 108: 2083-2092.
14. de Boer HC, Preissner KT, Bouma BN, de Groot PG (1992). Binding of vitronectin-thrombin-antithrombin III complex to human endothelial cells is mediated by the heparin binding site of vitronectin. J Biol Chem 267: 2264-2268.
15. de Boer HC, Preissner KT, Bouma BN, de Groot PG (1995). Internalization of vitronectin-thrombin-antithrombin complex by endothelial cells leads to deposition of the complex into the subendothelial matrix. J Biol Chem 270: 30733-30740.
16. 5 integrins in avian neural crest cell adhesion and migration on vitronectin. Development 120: 2687-2702.
17. Dufourcq P, Louis H, Moreau C, Daret D, Boisseau MR, Lamaziere JMD, Bonnet J (1998). Vitronectin expression and interaction with receptors in smooth muscle cells from human atheromatous plaque. Arterioscler Thromb Vasc Biol 18: 168-176.
18. Echtermeyer F, Streit M, Wilcox-Adelman S, Saoncella S, Benhez F, Detmar M, Goetinck PF (2001). Delayed wound repair and impaired angiogenesis in mice lacking syndecan-4. J Clin Invest 107: R9-R14.
19. Edens RE, LeBrun LA, Linhardt RJ, Kaul PR, Weiler JM (2001). Certain high molecular weight heparin chains have high affinity for vitronectin. Arch Biochem Biophys 391: 278-285.
20. Eitzman DT, Westrick RJ, Nabel EG, Ginsburg D (2000). Plasminogen activator inhibitor-1 and vitronectin promote vascular thrombosis in mice. Blood 95: 577-580.
21. Elenius K, Salmivitra M, Inki P, Mali M, Jalkanen M (1990). Binding of human syndecan to extracellular matrix proteins. J Biol Chem 265: 17837-17843.
22. Erdman R, Stahl RC, Rothblum K, Chernousov MA, Carey DJ (2002). Schwann cell adhesion to a novel heparan sulfate binding site in the N-terminal domain of the α4 type V collagen is mediated by Syndecan-3. J Biol Chem 277: 7619-7625.
23. Francois PP, Preissner KT, Herrmann M, Haugland RP, Vaudaux P, Lew DP, Krause K-H (1999). Vitronectin interaction with glycosaminoglycans: Kinetics, structural determinants, and role in binding to endothelial cells. J Biol Chem 274: 37611-37619.
24. Gibson AD, Lamerdin JA, Zhuang P, Baburaj K, Serpersu EH, Peterson CB (1999). Orientation of heparin-binding sites in native vitronectin. J Biol Chem 274: 6432-6442.
25. 5 mediates vitronectin-dependent adhesion of retinoic-acid-differentiated neuroblastoma cells. Am J Pathol 150: 1631-1646.
26. 3 integrin adhesion mechanism for transformed cells. J Clin Invest 88: 1924-1932.
27. Gladson CL, Wilcox JN, Sanders L, Gillespie GY, Cheresh DA (1995). Cerebral microenvironment influences expression of the vitronectin gene in astrocytic tumors. J Cell Sci 108: 947-956.
28. Godyna S, Liau G, Popa I, Stefansson S, Argraves WS (1995). Identification of the low density lipoprotein receptor-related protein (LRP) as an endocytic receptor for thrombospondin-1. J Cell Biol 129: 1403-1410.
29. Hageman GS, Mullins RF, Russell SR, Johnson LV, Anderson DH (1999). Vitronectin is a constituent of ocular drusen and the vitronectin gene is expressed in human retinal pigmented epithelial cells. FASEB J 13: 477-484.
30. Hocking DC, Sottile J, Reho T, Fassler R, McKeown-Longo PJ (1999). Inhibition of fibronectin matrix assembly by the heparin-binding domain of vitronectin. J Biol Chem 274: 27257-27264.
31. Horowitz A, Tkachenko E, Simons M (2002). Fibroblast growth factor-specific modulation of cellular response by sydnecan-4. J Cell Biol 157: 715-725.
32. Hortin GL, Schilling M, Graham JP (1988). Inhibitors of the sulfation of proteins, glycoproteins, and proteoglycans. Biochem Biophys Res Commun 150: 342-348.
33. Huang W, Chiquet-Ehrismann R, Moyano JV, Garcia-Pardo A, Orend G (2001). Interference of Tenascin-C with Syndecan-4 binding to fibronectin blocks cell adhesion and stimulates tumor cell proliferation. Cancer Res 61: 8586-8594.
34. Huebsch JC, McCarthy JB, Diglio CA, Mooradian DL (1995). Endothelial cell interactions with synthetic peptides from the carboxyl-terminal heparin-binding domains of fibronectin. Circ Res 77: 43-53.
35. Humphries DE, Silbert JE (1988). Chlorate: A reversible inhibitor of proteoglycan sulfation. Biochem Biophys Res Commun 154: 365-371.
36. Humphries DE, Sugumaran G, Silbert JE (1989). Decreasing sulfation of proteoglycans produced by cultured cells. Meth in Enzymol 179: 428-434.
37. Jang YC, Tsou R, Gibran NS, Isik FF (2000). Vitornectin deficiency is associated with increased wound fibrinolysis and decreased microvascular angiogenesis in mice. Surgery 127: 696-704.
38. Klass C, Couchman JR, Woods A (2000). Control of extracellular matrix assembly by syndecan-2-proteoglycan. J Cell Sci 113: 493-506.
39. Kost C, Stuber W, Ehrlich HJ, Pannekoek H, Preissner KT (1992). Mapping of binding sites for heparin, plasminogen activator inhibitor-1, and plasminogen to vitronectin's heparin-binding region reveals a novel vitronectin-dependent feedback mechanism for the control of plasmin formation. J Biol Chem 267: 12098-12105.
40. Kumagai T, Lee I, Ono Y, Maeno M, Takagi M (1998). Ultra-structural localization and biochemical characterization of vitronectin in developing rat bone. Histochem J 30: 111-119.
41. 1: Structural characteristics of heparan sulfate chains with avidity to COOH-terminal heparin-binding domain of fibronectin. Exp Cell Res 256: 434-444.
42. Langford JK, Stanley MJ, Cao D, Sanderson RD (1998). Multiple heparan sulfate chains are required for optimal Syndecan-1 function. J Biol Chem 273: 29965-29971.
43. Liang OD, Rosenblatt S, Chhatwal GS, Preissner KT (1997). Identification of novel heparin-binding domains of vitronectin. FEBS Lett. 407: 169-172.
44. Liebersbach BF, Sanderson RD (1994). Expression of Syndecan-1 inhibits cell invasion into Type I collagen. J Biol Chem 269: 20013-20019.
45. Liu W, Litwack D, Stanley MJ, Langford JK, Lander AD, Sanderson RD (1998). Heparan sulfate proteoglycans as adhesive and anti-invasive molecules. J Biol Chem 273: 22825-22832.
46. Longley RL, Woods A, Fleetwood A, Cowling GJ, Gallagher JT (1999). Control of morphology, cytoskeleton and migration by syndecan-4. J Cell Sci 112: 3421-3431.
47. Lyon M, Rushton G, Askari JA, Humphries MJ, Gallagher JT (2000). Elucidation of the structural features of heparan sulfate important for interaction with the Hep-2 domain of fibronectin. J Biol Chem 275: 4599-4606.
48. Martinez-Morales JR, Marti E, Frade JM, Rodriguez-Tebar A (1995). Developmentally regulated vitronectin influences cell differentiation, neuron survival and process outgrowth in the developing chicken retina. Neurosci 68: 245-253.
49. 5 integrin functions as an endocytic receptor for vitronectin. J Cell Sci 111: 425-433.
50. Mostafavi-Pour Z, Askari JA, Whittard JD, Humphries MJ (2001). Identification of a novel heparin-binding site in the alternatively spliced IIICS region of fibronectin: Roles of integrins and proteoglycans in cell adhesion to fibronectin splice variants. Matrix Biol 20: 63-73.
51. Noszczyk BH, Klein E, Holtkoetter O, Krieg T, Majewski S (2002). Integrin expression in the dermis during scar formation in humans. Exp Dermatol 11: 311-318.
52. Numa F, Hirabayashi K, Kawasaki K, Sakaguchi Y, Sugino N, Suehiro Y, Suminami Y, Hirakawa H, Umayahara K, Nawata S, Ogata H, Kato H (2002). Syndecan-1 expression in cancer of the uterine cervix: Association with lymph node metastasis. Int J Oncol 20: 39-43.
53. Odrljin TM, Francis CW, Sporn LA, Bunce LA, Marder VJ, Simpson-Haidaris PJ (1996). Heparin-binding domain of fibrin mediates its binding to endothelial cells. Arterioscler Thromb Vasc Biol 16: 1544-1551.
54. Oh E-S, Woods A, Couchman JR (1997). Multimerization of the cytoplasmic domain of syndecan-4 is required for its ability to activate protein kinase C. J Biol Chem 272: 11805-11811.
55. Oh E-S, Woods A, Couchman JR (1997). Syndecan-4 proteoglycan regulates the distribution and activity of protein kinase C. J Biol Chem 272: 8133-8136.
56. Oliver N, Newby RF, Furcht LT, Bourgeois S (1983). Regulation of fibronectin biosynthesis by glucocorticoids in human fibrosarcoma cells and normal fibroblasts. Cell 33: 287-296.
57. Ozaki S, Johnson LV, Mullins RF, Hageman GS, Anderson DH (1999). The human retina and retinal pigment epithelium are abundant sources of vitronectin mRNA. Biochem Biophys Res Comm 258: 524-529.
58. Panetti TS, McKeown-Longo PJ (1993). Receptor mediated endocytosis of vitronectin is regulated by its conformational state. J Biol Chem 268: 11988-11993.
59. 5 integrin receptor regulates receptor-mediated endocytosis of vitronectin. J Biol Chem 268: 11492-11495.
60. 5 integrin receptor-mediated endocytosis of vitronectin is protein kinase C-dependent. J Biol Chem 270: 18593-18597.
61. 3. J Biol Chem 272: 2736-2743.
62. Preissner KT, Seiffert D (1998). Role of vitronectin and its receptors in haemostasis and vascular remodeling. Thromb Res 89: 1-21.
63. Preissner KT, Muller-Berghaus G (1986). S-protein modulates the heparin-catalyzed inhibition of thrombin by antithrombin III. Eur J Biochem 156: 645-650.
64. Preissner KT, Muller-Berghaus G (1987). Neutralization and binding of heparin by S-protein/vitronectin in the inhibition of factor Xa by anti-thrombin III. J Biol Chem 262: 12247-12253.
65. Rapraeger AC, Ott VL (1998). Molecular interactions of the syndecan core proteins. Curr Opin Cell Biol 10: 620-628.
66. Sanderson RD, Borset M (2002). Syndecan-1 in B lymphoid malignancies. Ann Hematol 81: 125-135.
67. Sanderson RD, Turnbull JE, Gallagher JT, Lander AD (1994). Fine structure of heparan sulfate regulates syndecan-1 function and cell behavior. J Biol Chem 269: 13100-13106.
68. Saoncella S, Echtermeyer F, Denhez F, Nowlen J, Mosher DF (1999). Syndecan-4 signals cooperatively with integrins in a Rho-dependent manner in the assembly of focal adhesions and actin stress fibers. Proc Natl Acad Sci 96: 2805-2810.
69. Scaffidi AK, Moodley YP, Weichselbaum M, Thompson PJ, Knight DA (2001). Regulation of human lung fibroblast phenotype and function by vitronectin and vitronectin integrins. J Cell Sci 114: 3507-3516.
70. Seiffert D (1997). The glycosaminoglycan binding site governs ligand binding to the somatomedin β domain of vitronectin. J Biol Chem 272: 9971-9978.
71. Seiffert D, Iruela-Arispe ML, Sage EH, Loskutoff DJ (1995). Distribution of vitronectin mRNA during murine development. Develop Dynamics 203: 71-79.
72. Seiffert D, Keeton M, Eguchi Y, Sawdey M, Loskutoff DJ (1991). Detection of vitronectin mRNA in tissues and cells of the mouse. Proc Natl Acad Sci USA 88: 9402-9406.
73. Seiffert D, Smith JW (1997). The cell adhesion domain in plasma vitronectin is cryptic. J Biol Chem 272: 13705-13710.
74. Shaltiel S, Schvartz I, Korc-Grodzicki B, Kreizman T (1993). Evidence for an extra-cellular function for protein kinase A. Molec Cell Biochem 127/128: 283-291.
75. Sobel M, Soler DF, Kermode JC, Harris RB (1992). Localization and characterization of a heparin binding domain peptide of human von Willebrand factor. J Biol Chem 267: 8857-8862.
76. Stepp MA, Gibson HE, Gala PH, Iglesia DD, Pajoohesh-Ganji A, Pal-Ghosh S, Brown M, Aquino C, Schwartz AM, Goldberger O, Hinkes MT, Bernfield M (2002). Defects in keratinocyte activation during wound healing in the syndecan-1 deficient mouse. J Cell Sci 115: 4517-4531.
77. Suzuki S, Pierschbacher MD, Hayman EG, Nguyen K, Ohgren Y, Ruoslahti E (1984). Domain structure of vitronectin. J Biol Chem 259: 15307-15314.
78. Tomasini BR, Mosher DF (1990). Vitronectin. Prog Hemostasis Thromb 10: 269-305.
79. Tomasini-Johansson BR, Milbrink J, Pejler G (1998). Vitronectin expression in rheumatoid arthritic synovia - Inhibition of plasmin generation by vitronectin produced in vitro. Brit J Rheumatol 37: 620-629.
80. Tomasini-Johansson NR, Sundberg C, Lindmark G, Gailit JO, Rubin K (1994). Vitronectin in colorectal adenocarcinoma - Synthesis by stromal cells in culture. Exp Cell Res 214: 303-312.
81. Uchiyama H, Barut BA, Chauhan D, Cannistra SA, Anderson KC (1992). Characterization of adhesion molecules on human myeloma cell lines. Blood 80: 2306-2314.
82. Utani A, Nomizi M, Matsuura H, Kato K, Kobayashi T, Takeda U, Aota S, Nielsen PY, Shinkai H (2001). A unique sequence of the laminin α3 g domain binds to heparin and promotes cell adhesion through Syndecan-2 and -4. J Biol Chem 276: 28779-29788.
83. van Aken BE, Seiffert D, Thinnes T, Loskutoff DJ (1997). Localization of vitronectin in the normal and atherosclerotic human vessel wall. Histochem Cell Biol 107: 313-320.
84. 5 integrin to the basic domain of the HIV Tat protein and vitronectin. J Cell Biol 121: 461-468.
85. Wells MJ, Blajchman MA (1998). In vivo clearance of ternary complexes of vitronectin-thrombin-antithrombin is mediated by hepatic heparan sulfate proteoglycans. J Biol Chem 273: 23440-23447.
86. Wilcox-Adelman SA, Wilkins-Port CE, McKeown-Longo PJ (2000). Localization of urokinase type plasminogen activator to focal adhesions requires ligation of vitronectin integrin receptors. Cell Adhes Commun 7: 477-490.
87. Wilkins-Port CE, McKeown-Longo PJ (1998). Degradation of distinct forms of multimeric vitronectin by human fibroblasts. Biochim et Biophys Acta 1404: 353-366.
88. Wilkins-Port CE, McKeown-Longo P (1996). Heparan sulfate proteoglycans function in the binding and degradation of vitronectin by fibroblast monolayers. Biochem Cell Biol 74: 887-897.
89. Woods A (2001). Syndecans: Transmembrane modulators of adhesion and matrix assembly. J Clin Invest 107: 935-941.
90. Woods A, Longley RL, Tumova S, Couchman JR (2000). Syndecan-4 binding to the high affinity heparin-binding domain of fibronectin drives focal adhesion. Formation in fibroblasts. Arch Biochem Biophys 374: 66-72.
91. Worapamorn W, Xiao Y, Li H, Young WG, Bartold PM (2002). Differential expression and distribution of syndecan-1 and -2 in periodontal wound healing of the rat. J Peridontal Res 37: 293-299.
92. Yatohgo T, Izumi M, Kashiwagi H, Hayashi M (1988). Novel purification of vitronectin from human plasma by heparin affinity chromatography. Cell Struct Funct 13: 281-292.
93. Yoneda A, Ogawa H, Kojima K, Matsumoto I (1998). Characterization of the ligand binding activities of vitronectin: Interaction of vitronectin with lipids and identification of the binding domains for various ligands using recombinant domains. Biochemistry 37: 6351-6360.
94. Zellweger T, Ninck C, Mirlacher M, Annefeld M, Glass AG, Gasser TC, Mihatsch JJ, Gelmann EP, Bubendorf L (2003). Tissue microarray analysis reveals prognostic significance of syndecan-1 expression in prostate cancer. Prostate 55: 20-29.
95. Zhang G, Kim H, Cai X, Lopez-Guisa JM, Carmeliet P, Eddy AA (2003). Urokinase receptor modulates cellular and angiogenic responses in obstructure nephropathy. J Am Soc Nephrol 14: 1234-1253.
96. Zhao Y, Sane DC (1993). The cell attachment and spreading activity of vitronectin is dependent on the arg-gly-asp sequence; analysis by construction of RGD and domain deletion mutants. Biochem Biophys Res Comm 192: 575-582.
97. Zimmerman P, David G (1999). The syndecans, tuners of transmembrane signaling. FASEB J 13: S91-S100.